[CLLS] Cellectis S.A.

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 17.25 Change: 0.2 (1.17%)
Ext. hours: Change: 0 (0%)

chart CLLS

Refresh chart

Strongest Trends Summary For CLLS

CLLS is in the medium-term up 32% in 7 months and down -33% in 1 year. In the long-term down -67% below S&P in 3 years and down -83% below S&P in 7 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA ROE ROI
Current Ratio Quick Ratio Long Term Debt/Equity Debt Ratio
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities57.9 M Cash From Investing Activities-1.35 M Cash From Operating Activities41.73 M Gross Profit8.79 M
Net Profit6.14 M Operating Profit-3.56 M Total Assets339.77 M Total Current Assets331.52 M
Total Current Liabilities78.38 M Total Debt Total Liabilities77.89 M Total Revenue9.22 M
Technical Data
High 52 week27.01 Low 52 week9.73 Last close13.08 Last change-1.06%
RSI68.94 Average true range0.52 Beta1.53 Volume92.09 K
Simple moving average 20 days4.44% Simple moving average 50 days13.93% Simple moving average 200 days-14.55%
Performance Data
Performance Week-1.58% Performance Month25.29% Performance Quart4.56% Performance Half-22.42%
Performance Year-39.78% Performance Year-to-date-21.44% Volatility daily2.2% Volatility weekly4.93%
Volatility monthly10.1% Volatility yearly35% Relative Volume336.49% Average Volume112.61 K
New High New Low

News

2020-06-01 07:56:11 | Cellectis' Shares March Higher, Can It Continue?

2020-05-18 16:30:10 | Cellectis Appoints Biopharma Veteran Leopold Bertea as Senior Vice President of Technical Operations - Europe

2020-05-13 09:08:01 | How Cellectis CLLS Stock Stands Out in a Strong Industry

2020-05-12 16:30:10 | Monthly information on share capital and company voting rights

2020-05-12 10:02:02 | Top Ranked Momentum Stocks to Buy for May 12th

2020-05-11 16:30:10 | Cellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020

2020-05-09 14:00:32 | Cellectis SA CLLS Q1 2020 Earnings Call Transcript

2020-05-08 06:00:12 | Cellectis S.A. EPA:ALCLS Analysts Are Cutting Their Estimates: Here's What You Need To Know

2020-05-06 16:30:10 | Cellectis Provides Business Update and Reports Financial Results for First Quarter 2020

2020-04-30 18:13:08 | Gilead, Takeda Rumored to Have Sights on Iovance

2020-04-29 16:30:10 | Cellectis to Hold First Quarter 2020 Earnings Call on Thursday, May 7, 2020 at 7:30 AM EDT

2020-04-13 16:30:10 | Cellectis Appoints Carrie Brownstein, M.D., as Chief Medical Officer

2020-04-10 17:00:10 | Monthly information on share capital and company voting rights

2020-04-02 12:00:04 | What Makes Cellectis S.A. CLLS a New Strong Buy Stock

2020-03-27 11:09:03 | Cellectis Enters Oversold Territory

2020-03-10 16:30:00 | US Patent Covering CRISPR-Edited Allogeneic CAR T-Cells Granted to Cellectis

2020-03-06 16:30:00 | Cellectis: Monthly Information on Share Capital and Company Voting Rights

2020-03-04 16:30:00 | Cellectis Provides Business Update and Reports 4th Quarter and Full Year 2019 Financial Results

2020-03-04 16:05:00 | Cellectis and Servier Execute the Amendment Confirming the Expansion of Their Collaboration on UCART19 Products

2020-02-25 16:30:00 | Cellectis to Hold Fourth Quarter and Full Year 2019 Earnings Call on Thursday, March 5, 2020 at 7:30 AM EST

2020-02-21 12:00:05 | Cellectis S.A. CLLS Moves to Strong Buy: Rationale Behind the Upgrade

2020-02-18 16:30:00 | Cellectis and Servier Expand Collaboration on UCART19 Products

2020-02-07 17:00:00 | Cellectis: Monthly Information on Share Capital and Company Voting Rights

2020-01-27 23:01:28 | Imagine Owning Cellectis EPA:ALCLS And Wondering If The 43% Share Price Slide Is Justified

2020-01-15 16:30:00 | First Patient Dosed with Cellectis’ New Allogeneic UCART123 Product Candidate for Relapsed/Refractory Acute Myeloid Leukemia

2020-01-13 16:15:10 | Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs

2020-01-09 16:30:00 | Cellectis: Monthly Information on Share Capital and Company Voting Rights

2020-01-06 16:30:00 | Cellectis: An Expert Review on Allogeneic CAR-T for Cancer Published in Nature Reviews Drug Discovery

2020-01-02 09:16:02 | Keysight, Analog Devices, Alexion, Amarin and Cellectis highlighted as Zacks Bull and Bear of the Day

2019-12-31 08:45:01 | 3 Biotech Stocks Likely to Maintain Solid Momentum in 2020

2019-12-17 11:13:20 | Gilead's Second CAR-T Treatment Suffers the Same Issues as Yescarta

2019-12-02 16:30:00 | 1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

2019-11-21 07:22:05 | The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon

2019-11-20 16:30:00 | Cellectis Wins Patent Challenge in Europe for a Method Using CRISPR-Cas9 for Gene Editing in T-Cells

2019-11-13 16:30:00 | Cellectis Publishes Creation of “Smart CAR T-Cells” for Potentially Safer, More Effective Treatments for Cancer in Nature Communications

2019-11-06 16:47:00 | Cellectis Reports Financial Results for Third Quarter and First Nine Months 2019

2019-10-31 16:30:00 | Cellectis to Hold Third Quarter and First Nine Months 2019 Earnings Call on Thursday, November 7, 2019 at 8:00 AM EST

2019-10-30 01:15:34 | We're Keeping An Eye On Cellectis's EPA:ALCLS Cash Burn Rate

2019-10-29 16:30:00 | First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma

2019-10-04 13:02:18 | 2 Falling Knives Expected to Rebound

2019-10-01 16:30:00 | Cellectis and Lonza Enter cGMP Manufacturing Service Agreement for Cellectis’ Allogeneic UCART Product Candidates

2019-09-15 04:23:28 | Does Cellectis S.A. EPA:ALCLS Have A Particularly Volatile Share Price?

2019-08-06 16:30:00 | Cellectis Reports Financial Results for Second Quarter and First Six Months 2019

2019-07-08 16:30:00 | Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way

2019-06-26 16:30:00 | Cellectis S.A. Reports Results from Combined Shareholders Meeting Held on June 25, 2019

2019-05-07 16:32:00 | Cellectis Reports Financial Results for First Quarter 2019

2019-04-17 16:30:00 | Cellectis Announces Oral and Poster Presentations of Allogeneic CAR T-Cell Programs at the 2019 ASGCT Annual Meeting

2019-04-03 08:19:01 | The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

2019-04-02 16:30:00 | FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients

2019-03-11 16:10:00 | Cellectis Reports 4th Quarter and Full Year 2018 Financial Results